ESMO Congress 2024 GU Round-Up: Kidney Cancer

By Christopher Wallis, MD, PhD, FRCSC, Karine Tawagi, MD - Last Updated: September 23, 2024

At the ESMO Congress 2024, Karine Tawagi, MD, of University of Illinois, and Christopher Wallis, MD, PhD, of University of Toronto, provide an overview of some of the most relevant research updates from the meeting in renal cell carcinoma.

Among the highlights are the SUNNIFORECAST and TiNivo-2 trials.

The Journey to a Personalized Vaccine: Dr. David Braun on Neoantigen mRNA Therapy in RCC

David Braun, MD, PhDAdvanced Renal Cell Carcinoma | March 24, 2025

Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.

Impact of Insurance Status on Survival Outcomes in Metastatic RCC

Emily MenendezAdvanced Renal Cell Carcinoma | March 19, 2025

Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.

Ipi/Nivo Provides Better OS & FS in Older Adult Populations With mRCC

Emily MenendezAdvanced Renal Cell Carcinoma | February 25, 2025

The combination therapy provided similar survival rates and toxicity in an older patient population.

Extensive Necrosis as a Prognostic Indicator in mRCC Treated With Deferred Cytoreductive Nephrectomy After ICI Treatment

Daniel Joyce, MDRenal Cell Carcinoma | February 24, 2025

Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.

Treatment Characteristics, Survival Rates, and Costs of IO/IO and IO/TKI Therapies for mRCC

Emily MenendezAdvanced Renal Cell Carcinoma | January 29, 2025

First-line IO + IO therapy is linked to higher costs during the first three months of treatment.

ESMO Congress 2024 GU Round-Up: Kidney Cancer

Related Posts